HER2 expression status in diverse cancers: review of results from 37,992 patients.
about
HER2 testing in gastric cancer: An updateHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsDirect protein quantification in complex sample solutions by surface-engineered nanorod probesPrognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniquesMolecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.The Conundrum of Genetic "Drivers" in Benign Conditions.HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method.Therapeutic implication of HER2 in advanced biliary tract cancer.The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.Emerging Therapeutic Targets for Male Germ Cell Tumors.Pertuzumab in gastrointestinal cancer.Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patientsPhase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines.Minimalist Antibodies and Mimetics: An Update and Recent Applications.The evolving genomic landscape of urothelial carcinoma.Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).Driving better and safer HER2-specific CARs for cancer therapy.Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor.Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer.Current Advances in Aptamers for Cancer Diagnosis and Therapy.Different stages in drug development for muscle-invasive bladder cancer.Practical guidance for mismatch repair-deficiency testing in endometrial cancer.The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma.Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumorsHER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancerThe HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
P2860
Q26746253-CB2AE188-DB62-4CB6-A798-695E46BEEB12Q28078111-D60585C8-1205-4823-8D66-66D51CFD50CBQ33881483-F1FA834D-32FA-4129-B79A-CE2D9B04FFD0Q36107543-271E3EA9-DCD4-4616-8C6F-385FD3935554Q36544915-A16D3020-AB71-4ED4-B027-0FA8F88BCBACQ37017110-05C20C89-3CD2-4F5C-918B-FA1D14263BB4Q37245787-6DE8ABEB-0E28-4010-BF9E-31BA4A4CD4DBQ37582166-1845B3CC-48B8-4337-BE57-C5437AAC2330Q37628969-86012154-6964-4465-A9F9-F48F94D78743Q38598710-F6F3CC40-A9EB-4A5E-B6D4-1ECCC0B4D426Q38602699-430C5A2B-1ABC-458B-AD78-D796EFE4D1DBQ38653309-9A08B3C9-0F5E-4170-81D0-CAAFBF4E15FAQ38669870-FAAEB275-40E5-4318-AE56-9BAD0DFB5338Q38677904-AD31B560-77AE-4550-9D8C-8FB19E9F39E9Q38729531-5580F4FB-AAB8-4C72-AA92-509E9911C9DDQ38914281-88A7E93F-3B1D-49EC-855C-A1B8DF06A4D9Q39124491-FF618DB2-2638-4B1F-B2F9-B109384B7FD9Q39751816-949D0086-BE26-4563-90F2-743FAC87C906Q40713928-AEDB87FB-045C-4BDA-B072-DB91A190A428Q41835996-C30CD159-7D4C-4D51-BE94-D6A6D74FBEC6Q44846795-80AC950A-340B-45C9-A35E-5A4121DCD3FEQ46538042-3CC45EC0-A348-49C8-B609-5F7F7FAB5BFBQ47134263-D92C8C00-DB6E-4C9A-9EA2-33A9F9914423Q47136892-251665EE-D15D-4AFE-A116-17C0DF20B65BQ47281580-B6723B53-72C2-46F0-8A60-CE02540C2CDAQ47418290-A9631AB8-2815-485F-9085-122C6322CA02Q47561686-12D62084-E8F6-46CA-9B1D-BC867D7EE6DDQ48022703-AAE23837-CD4B-4DC2-9686-B612A50CEF58Q48478518-C79CA954-4343-4CD0-9EE1-EE6F4C12C09BQ50049202-53256871-7078-4EAE-A61C-64855DD39C48Q51180085-8B050F7B-9E14-49C2-829E-80FEB7D8A185Q52657511-86EB5F99-FFD1-4A1B-9290-E15F24F6667FQ56348401-E02E4130-9F18-4DCB-B946-CB9CCF41A45FQ57109545-C6D37E4D-3B42-482C-9626-704590F18378Q58601441-32B963FF-6DE7-497F-8623-AD79B3579AC0
P2860
HER2 expression status in diverse cancers: review of results from 37,992 patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
HER2 expression status in diverse cancers: review of results from 37,992 patients.
@en
type
label
HER2 expression status in diverse cancers: review of results from 37,992 patients.
@en
prefLabel
HER2 expression status in diverse cancers: review of results from 37,992 patients.
@en
P2093
P2860
P1476
HER2 expression status in diverse cancers: review of results from 37,992 patients.
@en
P2093
David Arguello
Sherri Z Millis
Zoran Gatalica
P2860
P2888
P304
P356
10.1007/S10555-015-9552-6
P577
2015-03-01T00:00:00Z
P5875
P6179
1015188240